Heart failure & cardiomyopathiesRandomised controlled trial
Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen
- Baseline characteristics report of the CARDIO-TTRansform randomised trial
- blinded baseline data
Authors' conclusion
The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of care for ATTR-CM.
Study context
- Population
- Patients with ATTR-CM enrolled in CARDIO-TTRansform, March 2020 to July 2023
- Participants
- 1,432 patients
- Comparison
- Eplontersen vs placebo
Primary result
As reported in the abstract
Baseline characteristics · baseline
- Mean (SD) age, years
- 76.4 (7.1)
- Female
- 9.4%
- White
- 88.8%
- Hereditary/variant ATTR-CM (ATTRv-CM)
- 211 (14.7%)
- Val122Ile (p.Val142Ile), most common genotype, n
- 130
- NYHA class I, n
- 192
- NYHA class II, n
- 997
- NYHA class III, n
- 243
- National Amyloidosis Centre disease stage 1
- 62.6%
- Median (IQR) NT-proBNP, pg/ml
- 2025 (1296-3465)
- NT-proBNP >8500 pg/ml, n
- 51
- Median (IQR) high-sensitivity troponin T, pg/ml
- 50 (35-69)
- Mean LVEF (SD)
- 55.7% (9.7%)
- On TTR stabiliser
- 57.2%
- On SGLT2 inhibitors
- 18.4%
Original publication
Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. Eur J Heart Fail. Published 30 May 2026. doi:10.1093/ejhf/xuag168
Summarised from the published abstract; every number is checked against it